Bristol-Myers Squibb (NYSE:BMY) on Saturday announced results from a late-stage trial for its psoriasis therapy Sotyktu in psoriatic arthritis, noting that more than 50% of trial participants who ...
New 5-year data on the efficacy and safety of Sotyktu show consistent results for adults with moderate to severe psoriasis. Rates of serious adverse events were similar to other psoriasis treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback